Anti-Human CFD Reference Antibody (Lampalizumab, RUO) (HF697016)

Name: Anti-Human CFD Reference Antibody (Lampalizumab, RUO)
Brand: abinScience
SKU: HF697016
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HF697016
Descripción	Lampalizumab (HF697016) is a research-grade recombinant antibody targeting PFD. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	Fab-G1-kappa
Sistema de expresión	Mammalian cells
Objetivo	PFD, Adipsin, C3 convertase activator, Complement factor D, CFD, DF, Properdin factor D
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P00746
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	AFD, Anti-fD, Anti-FACTORD, FCFD4514S, RG7417, 1278466-20-8
Fondo	Complement factor D (CFD) is a ~27 kDa protein. Serine protease that initiates the alternative pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. In contrast to other complement pathways (classical, lectin and GZMK) that are directly activated by pathogens or antigen-antibody complexes, the alternative complement pathway is initiated by the spontaneous hydrolysis of complement C3. The alternative complement pathway acts as an amplification loop that enhances complement activation by mediating the formation of C3 and C5 convertases. Activated CFD cleaves factor B (CFB) when the latter is complexed with complement C3b, activating the C3 convertase of the alternative pathway. 1. Forneris, F. et al. (2010) Science (New York, N.Y.) 330, 1816-20. PMID: 21205667 2. Katschke, KJ. et al. (2012) The Journal of biological chemistry 287, 12886-92. PMID: 22362762 3. Niemann, MA. et al. (1980) Biochemistry 19, 1576-83. PMID: 6769474 4. Volanakis, JE. et al. (1977) Journal of immunology (Baltimore, Md. : 1950) 119, 337-42. PMID: 874324 5. Hourcade, DE. et al. (1998) The Journal of biological chemistry 273, 25996-6000. PMID: 9748277
Nota	For research use only. Not suitable for clinical or therapeutic use.